First interim safety analysis of a phase III randomized trial in a newly diagnosed systemic peripheral T-cell lymphoma trated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant.

Francesco Annibale D'Amore, M Gomes da Silva, S Leppa, T Relander, A Pezzutto, GF Lauritzsen, E Weidmann, M Van Gelder, M Merup, H Hagberg, UM Fagerli, Peter De Nully Brown, P Boye Hansen, JM Mariz, M Jankovska, J Walewski, J Doorduijn, A van Hoof, Ilse Christiansen, S JyrkkiöJC Kluin-Nelemans, M van Marwijk Kooy, R Fijnheer, W Stevens, J Zijlstra, L Böhmer, PJ Lugtenburg, M Grube, V Prochazka, D Salek, R Greil, L Trümper, G Wulf, B Altmann, M Ziepert, M Loeffler, E Jantunen, G Hopfinger, E Van den Neste, H Toldbod

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind118
Sider (fra-til)4110
ISSN0006-4971
StatusUdgivet - 2011
Udgivet eksterntJa

Citationsformater